NERX Neorx (MM)

Company to Provide Update on Ongoing Phase II Trial of Picoplatin in Small Cell Lung Cancer SEATTLE, Nov. 1 /PRNewswire-FirstCall/ -- NeoRx Corporation (NASDAQ:NERX), a cancer therapeutics development company, today announced that Jerry McMahon, Ph.D., chairman and CEO of NeoRx, will present at the Rodman & Renshaw Techvest 7th Annual Healthcare Conference on Monday, November 7, at 8:20 a.m. at the New York Palace Hotel in New York. Dr. McMahon will provide an update on the ongoing Phase II trial of picoplatin, a next-generation platinum therapy, in patients with small cell lung cancer. The trial is currently open to enrollment at clinical sites throughout the United States and in Canada. A live audio webcast will be available from the NeoRx web site (http://www.neorx.com/) under the "Investors" section. A replay of the presentation will also be available for 10 days. About NeoRx NeoRx is a cancer therapeutics development company. The Company currently is focusing its development efforts on picoplatin (NX 473), a next-generation platinum therapy designed to overcome platinum-based chemoresistance. A Phase II trial of picoplatin is presently underway for patients with small cell lung cancer. The Company plans to undertake multiple combination trials in solid tumors next year. NeoRx also is collaborating with the Scripps Florida research institute on the discovery of novel, small-molecule, multi-targeted protein kinase inhibitors for the treatment of cancer. For more information, visit http://www.neorx.com/. This release contains forward-looking statements relating to the development of the Company's products which are subject to certain risks and uncertainties that could cause actual results to differ materially from those projected. The words "believe," "expect," "intend", "anticipate", "plan", variations of such words, and similar expressions identify forward-looking statements, but their absence does not mean that the statement is not forward- looking. These statements are not guarantees of future performance and are subject to certain risks, uncertainties and assumptions that are difficult to predict. Factors that could affect the Company's actual results include the effect of the risks that the Company is unable to raise additional capital sufficient to continue to fund its picoplatin program and future operations, the uncertainty and timing of obtaining additional financing, actions by the FDA and other regulators, the Company's ability to obtain required regulatory approvals, the progress and costs of the Company's picoplatin clinical trials, the Company's ability to generate future revenue from product sales or other sources such as collaborative relationships and future profitability, the Company's dependence on patents and other proprietary rights, and the other risks and uncertainties described in the Company's current and periodic reports filed with the Securities and Exchange Commission, including NeoRx's Annual Report on Form 10-K for the year ended December 31, 2004 and its most recent Quarterly Report on Form 10-Q. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this release. The Company undertakes no obligation to update any forward-looking statement to reflect new information, events or circumstances after the date of this release or to reflect the occurrence of unanticipated events. DATASOURCE: NeoRx Corporation CONTACT: Julie Rathbun, Corporate Communications of NeoRx Corporation, +1-206-286-2517, or Web site: http://www.neorx.com/

Copyright